[HTML][HTML] Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours
C Horbinski, T Berger, RJ Packer, PY Wen - Nature Reviews Neurology, 2022 - nature.com
A new edition of the WHO classification of tumours of the CNS was published in 2021.
Although the previous edition of this classification was published just 5 years earlier, in …
Although the previous edition of this classification was published just 5 years earlier, in …
Glioblastoma: clinical presentation, diagnosis, and management
• Early symptoms of brain tumours in adults are non-specific, and patients may present
multiple times to primary care services before they are referred for investigation. Look for …
multiple times to primary care services before they are referred for investigation. Look for …
Vorasidenib in IDH1-or IDH2-mutant low-grade glioma
IK Mellinghoff, MJ Van Den Bent… - … England Journal of …, 2023 - Mass Medical Soc
Background Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas are malignant brain
tumors that cause considerable disability and premature death. Vorasidenib, an oral brain …
tumors that cause considerable disability and premature death. Vorasidenib, an oral brain …
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
M Lim, M Weller, A Idbaih, J Steinbach… - Neuro …, 2022 - academic.oup.com
Background Nearly all patients with newly diagnosed glioblastoma experience recurrence
following standard-of-care radiotherapy (RT)+ temozolomide (TMZ). The purpose of the …
following standard-of-care radiotherapy (RT)+ temozolomide (TMZ). The purpose of the …
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase …
A Omuro, AA Brandes, AF Carpentier, A Idbaih… - Neuro …, 2023 - academic.oup.com
Background Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival
(OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with …
(OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with …
[HTML][HTML] Transcriptome analysis reveals tumor microenvironment changes in glioblastoma
Y Hoogstrate, K Draaisma, SA Ghisai, L van Hijfte… - Cancer Cell, 2023 - cell.com
A better understanding of transcriptional evolution of IDH-wild-type glioblastoma may be
crucial for treatment optimization. Here, we perform RNA sequencing (RNA-seq)(n= 322 test …
crucial for treatment optimization. Here, we perform RNA sequencing (RNA-seq)(n= 322 test …
[HTML][HTML] Artificial-intelligence-based molecular classification of diffuse gliomas using rapid, label-free optical imaging
Molecular classification has transformed the management of brain tumors by enabling more
accurate prognostication and personalized treatment. However, timely molecular diagnostic …
accurate prognostication and personalized treatment. However, timely molecular diagnostic …
World Health Organization 2021 classification of central nervous system tumors and implications for therapy for adult-type gliomas: a review
TR Berger, PY Wen, M Lang-Orsini… - JAMA …, 2022 - jamanetwork.com
Importance Previous histologic classifications of brain tumors have been limited by
discrepancies in diagnoses reported by neuropathologists and variability in outcomes and …
discrepancies in diagnoses reported by neuropathologists and variability in outcomes and …
[HTML][HTML] Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial
CE Brown, JC Hibbard, D Alizadeh, MS Blanchard… - Nature medicine, 2024 - nature.com
Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve
treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current …
treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current …
Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group
Background Terminology to describe extent of resection in glioblastoma is inconsistent
across clinical trials. A surgical classification system was previously proposed based upon …
across clinical trials. A surgical classification system was previously proposed based upon …